All ongoing clinical trials of rusfertide to resume dosing
Phase 3 registrational trial planned to commence in the first quarter of 2022
Conference call scheduled for today at 8:00 A.M. ET
A conference call will take place today, October 11, 2021, at 8:00 a.m. ET.
Live audio of the conference call will be simultaneously broadcast over the internet. The call will be available to investors, members of the news media, and the general public.
To access the live call, dial (877) 870-4263 (U.S./Canada) or (412) 317-0790 (international) five minutes prior to the call and ask to be joined to the Protagonist Therapeutics call. A live and archived webcast will be accessible in the Investors section of the Company's website at www.protagonist-inc.com.
https://finance.yahoo.com/news/protagonist-therapeutics-announces-removal-fda-110000856.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.